Ascendis Pharma A/S (BVMF:A1SN34)

Revenue

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
YORVIPATH Revenue	629.62M	477.41M	28.73M
YORVIPATH Revenue Growth	31.88%	1561.89%	-
SKYTROFA Revenue	198.78M	206.16M	197.00M
SKYTROFA Revenue Growth	-3.58%	4.65%	10.26%
Commercial Products Revenue	828.40M	683.57M	225.73M
Commercial Products Revenue Growth	21.19%	202.83%	26.34%
Services and Clinical Supply Revenue	19.59M	18.01M	15.57M
Services and Clinical Supply Revenue Growth	8.81%	15.66%	-29.16%
Licenses Revenue	4.87M	5.63M	122.34M
Licenses Revenue Growth	-13.57%	-95.40%	85.15%
Milestones Revenue	-	12.92M	-
Revenue (Other)	12.92M	-	-
Revenue (Total)	865.78M	720.13M	363.64M
Revenue (Total) Growth	20.23%	98.03%	36.34%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	681.78M	546.39M	233.12M
United States Revenue Growth	24.78%	134.39%	21.62%
Europe Revenue	135.94M	120.95M	123.34M
Europe Revenue Growth	12.39%	-1.94%	14092.86%
Rest of World Revenue	48.06M	52.80M	7.19M
Rest of World Revenue Growth	-8.97%	634.33%	-90.31%
Revenue (Total)	865.78M	720.13M	363.64M
Revenue (Total) Growth	20.23%	98.03%	36.34%

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Number of Unique U.S. Patient Enrollments - YORVIPATH	6.30K	5.30K	908.00
Number of Unique U.S. Patient Enrollments - YORVIPATH Growth	18.87%	483.70%	-
Number of Unique Prescribing Healthcare Providers - YORVIPATH	2.70K	2.40K	539.00
Number of Unique Prescribing Healthcare Providers - YORVIPATH Growth	12.50%	345.27%	-

Data Source: Fiscal.ai Last updated: Mar 31, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 30, 2026

Data Sources Report a data error